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1. Introduction
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes is a series
of Editorials, which is published on a biannual basis by the Editorial Board of the Medicinal Chemistry
section of the journal Molecules. In these Editorials, we highlight in brief reports (of about one hundred
words) a number of recently published articles that describe crucial findings, such as the discovery
of novel drug targets and mechanisms of action, or novel classes of drugs, which may inspire future
medicinal chemistry endeavors devoted to addressing prime unmet medical needs.
2. A Hydrogen Peroxide Sensitive Prodrug Strategy for the Targeted Delivery of Methotrexate in
Rheumatoid Arthritis
Highlighted by Arduino A. Mangoni
Systemic exposure to methotrexate, an anti-inflammatory and immunomodulating drug,
is associated with haematological, gastrointestinal, and lung toxicity. A targeted drug delivery
in tissues affected by inflammation might retain therapeutic efficacy whilst preventing exposure
to normal organs and tissues. Peiró Cadahía et al. investigated a methotrexate prodrug strategy
consisting of a reactive oxygen species-labile 4-methylphenylboronic acid linked to methotrexate via a
carbamate linkage, that led to the synthesis of a novel prodrug, (4-(((2-amino-4-((((4-boronobenzyl)oxy)
carbonyl)amino)pteridin-6-yl)methyl)(methyl)amino)benzoyl)-L-glutamic acid [1]. Incubation of this
prodrug with reactive oxygen species, at concentrations similar to those observed in inflammatory
tissues, led to the exclusive release of methotrexate. In an animal model of inflammatory arthritis,
this prodrug significantly reduced the macroscopic arthritis score when compared to the control group.
The effect of the prodrug on the arthritis score was similar to that observed with methotrexate. Notably,
progressive weight loss, a marker of toxicity, was observed with methotrexate, but not with the prodrug.
A hydrogen peroxide sensitive prodrug strategy for the targeted delivery of methotrexate is a novel,
promising, approach for the treatment of patients with rheumatoid arthritis.
3. A Novel Modulator of Rod Opsin Showing in Vivo Efficacy for Retinal Degeneration
Highlighted by Tiziano Tuccinardi
Mutations destabilizing rod opsin are one of the main factors that lead to retinal degeneration.
Focusing on the analysis on the P23H rod opsin mutation, that is the most common mutation among
autosomal dominant retinis pigmentosa patients in North America, Palczewski and co-workers
reported compound YC-001 as the first non-retinal modulator of rod opsin with both inverse and
non-competitive antagonist activities [2]. YC-001 was discovered by a cellular high-throughput
screening; it showed an interesting activity in various in vitro binding assays, and showed in vivo
efficacy in a mouse model of bright light-induced retinal degeneration, thus supporting the possible
therapeutic application of this compound. The authors were not able to obtain a crystal structure of
the YC-001:opsin complex; however, this study paves the way for the design and development of new
candidate drugs for the treatment of pathologies associated with retinal degeneration.
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4. Combining Innovative 2D NMR Techniques and Deep Neural Networks to Assist Natural
Products Discovery
Highlighted by Simona Collina
In Nature-Aided-Drug-Discovery process, compound structure determination and extract
dereplication are crucial and extremely time-consuming steps. To speed up the research in the field of
natural compounds, the interdisciplinary team coordinated by Cottrell and Gerwick recently developed
a tool called the Small Molecule Accurate Recognition Technology (SMART) [3]. The SMART tool uses
a piece of spectral data which is unique and characteristic to each molecule, and runs it through a
deep learning neural network to place the unknown molecule in a cluster of molecules with similar
structures. In more detail, the HSQC-NMR of each compound produces a topological map of spots,
and the Convolutional Neural Network (CNN) learning system takes the images of spectra of unknown
molecules and maps them into a ten-dimensional space near molecules with similar traits. As the
Authors stated, it is possible to associate and integrate biological, pharmacological, and ecological data
with SMART, and thereby create new tools for enhanced discovery and development of biologically
active natural products. Of note, SMART is not a “closed system”, and the continuous, further addition
of compounds to the training set will improve accuracy and robustness of the system, thus accelerating
natural product structural elucidation.
5. Sertraline, Paroxetine, and Chlorpromazine are Rapidly Acting Anthelmintic Drugs Capable of
Clinical Repurposing
Highlighted by Jean Jacques Vanden Eynde
Accelerating the identification of promising drug candidates and decreasing the costs associated
with getting them to market are among the most important goals for the pharmaceutical industry [4].
A recent publication by J.C. Weeks et al. [5] has opened new doors in the search for innovative
treatments of helminth (worm) infections. The authors performed a high-throughput screening of
218 compounds from the NIH Clinical Collection aimed at identifying hits that can perturb the life
cycle of Caenorhabditis elegans, a nematode worm often used as a model for many human diseases.
Three common drugs emerged: sertraline, paroxetine, and chlorpromazine (Figure 1). The first two
are prescribed as antidepressants, whereas chlorpromazine is known as an antipsychotic. The study
discovered that the three drugs act on C. elegans through non-canonical modes of action, and also
measured their broad spectrum anti-parasitic effects against the parasitic nematodes, Trichuris and
Ancylostoma, and the Schistosoma flatworm. The authors concluded that repurposing these commercially
available medications, in combination with conventional anthelmintic drugs, could improve efficacy
and limit the emergence of drug-resistant helminths.
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6. Turning a Gram-Positive-Only into an Effective Gram-Negative Antibiotic Using the
Bacterial Machinery
Highlighted by Diego Muñoz-Torrero
Poor permeation through the outer membrane and degradation by β-lactamases are behind
the lack of activity of many antibiotics against Gram-negative bacteria, some of which are among
the most threatening pathogens for human health. Liu et al. have developed a very elegant
approach to killing Gram-negative bacteria, using a Gram-positive oxazolidinone antibiotic conjugated
with a cephalosporin and a bis-catechol-based siderophore [6]. The three-component conjugate
displays a very original mechanism of action, which takes advantage of (i) bacterial ferri-siderophore
uptake transporters to allow for the efficient passage of the conjugate through the outer membrane,
and (ii) the periplasmic β-lactamases, to cleave the β-lactam ring of the cephalosporin component
with a concomitant ultimate release of the oxazolidinone. The released oxazolidinone can then
cross the bacterial inner membrane and reach its intracellular ribosomal target, thereby killing the
Gram-negative bacteria, as demonstrated using clinical isolates of the cephalosporinase-producing,
highly troublesome pathogen Acinetobacter baumannii, and other Gram-negative bacteria, such as
Escherichia coli DC0 and Pseudomonas aeruginosa KW799. An ingenious way to convert Gram-positive
into Gram-negative effective antibiotics in the fight against multidrug resistant bacteria!
7. Cannabinoid-Induced Cell Death in Endometrial Cancer Cells: Involvement of TRPV1
Receptors in Apoptosis
Highlighted by Rafik Karaman
For centuries, cannabis has been utilized for tackling symptoms of a variety of diseases.
For instance, cannabis has been used for the treatment of cancer-related symptoms, like pain and
nausea. Cannabidiol (CBD), ∆9-tetrahydrocannabinol (THC), anandamide (AEA), endocannabinoids
(eCBs), and 2-arachidonoylglycerol (2-AG) are considered as promising agents for the treatment of
cancer patients. They have been shown to inhibit in vitro growth of tumor cells and induce tumor
cell death. Recently, in a study by Fonseca et al. on endometrial cancer (cancer of the uterus), it was
demonstrated that CBD is quite effective in causing death to many of the cancerous cells tested in
the lab, whereas no significant effect was observed with THC. Unraveling the mechanism of this
finding revealed that CBD was killing cancer cells by activating TRPV1 receptors, and the reduction in
cell viability was caused by the activation of the apoptotic pathway. TRPV1 receptors are known to be
one of CBD’s targets, and are not activated by THC. Thus, it was concluded that CBD is a promising
medication for those patients who are not responsive to the traditional treatments [7].
8. Fenarimols, New Drug Candidates for a Great Social Problem
Highlighted by Carlo Siciliano
Eumycetoma is a neglected but grave infectious disease. Its transmission is favored by both
geographical and economic factors, especially among resource-poor populations living in rural and
urban areas of tropical and subtropical countries. Blindness, disability, deformities, impairment of
childhood growth and development, and adverse pregnancy outcomes affect infected individuals.
The clinical treatment of this disease has a limited success rate and requires a combination of surgery
and prolonged pharmacological therapy. Conazoles have been the mainstay of medical treatment
for decades. However, the etiological agents remain viable after treatment with these potentially fatal
toxic drugs, which are usually too expensive for use in endemic regions.
A large class of fenarimol analogues has been subjected to in silico, in vitro, and in vivo screenings,
for their activity against the causative agents of mycetoma diseases [8]. Four analogues were
identified as the most efficient members of this class. A trifluoromethylaryl analogue of fenarimol
showed the highest therapeutic efficacy, due to its minimal inhibitory concentration, lack of toxicity,
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and significantly reduced treatment time. Today, this novel drug candidate might represent a renewed
and concrete hope to fast track and boost the discovery of cheaper therapies against socially important,
but neglected, tropical diseases.
9. Late-Stage Lead Diversification: Metabolism Giving a Helping Hand at the Nanomole Scale
Highlighted by Maria Emília de Sousa
Late-stage diversification has gained considerable attention in drug discovery. This strategy offers
the possibility of the rapid exploration of structure activity relationships (SAR), the preparation of
biological probes, the generation of oxidized metabolites, and the blocking of metabolic hot spots,
minimizing the risk for drug-drug interactions. Obach et al. [9] from Pfizer described a case-study of
phosphodiesterase-2 inhibitors in which late-stage lead diversifications were accomplished by drug
metabolism biosynthesis using P450 enzymes and liver microsomes. The breakthrough in this strategy
was the use of quantitative cryomicroprobe NMR spectroscopy that allowed the gathering of spectral
information at a submicromole scale. The authors reported how nanomole quantities of multiple
products can be prepared simultaneously, screened, scaled-up, products isolated, and analyzed by
quantitative NMR spectroscopy within a few days. One can imagine the investigation of alternative
(bio)transformations which could be undertaken by applying this strategy.
10. Controlling Insatiable Appetite with a Melanocortin-4 Receptor Agonist in Patients with
Leptin Receptor Defect
Highlighted by Katalin Prokai-Tatrai
Leptin receptor mutations result in disruption of the satiety center within the brain, leading to
insatiable appetite, and consequently, severe obesity. This condition cannot be treated permanently
by weight loss surgery, highlighting the need for safe and efficacious pharmacological interventions.
In a recent pilot study [10], it has been shown that individuals with specific leptin receptor deficiency
responded well to the melanocortin-4 receptor (MC4R) agonist setmelanotide. MC4R is essential for
transducing the satiety signal to the body. Setmelanotide is a peptide with the sequence acetyl-L-
arginyl-cyclo[L-cysteinyl-D-alanyl-L-histidinyl-D-phenylalanyl-L-arginyl-L-tryptophanyl-L-cysteinyl]
-amide, which was injected subcutaneously once per day to the subjects. Treatments with this peptide
resulted in substantial and sustained loss of appetite and body weight without significant side effects,
such as cardiovascular liability. The researchers have also discovered a new mechanism of action
for setmelanotide that may explain its efficacy over other MC4R agonists. Altogether, the findings
in this paper raise hope to counter genetic obesity in individuals suffering from deficiency in the
hypothalamic leptin-melanocortin pathway.
11. Phosphate Prodrug Strategy Is Applicable in Colon Drug Delivery
Highlighted by Jarkko Rautio
Phosphate prodrug strategy where a phosphate group is either directly attached, or through a
short linker such as OCH2 to the parent drug, has been very successful in improving dissolution-limited
and/or solubility-limited oral absorption. In this paper [11], the design of phosphonooxymethyl
prodrug was explored for the anti-HIV-1 agent, temsavir, which is categorized as a biopharmaceutics
classification system (BCS) class II drug (low solubility and high permeability). The prodrug showed
significantly higher aqueous solubility (>11 mg/mL at pH 1.5–8.2) than temsavir (~20 µg/mL at
pH 2–9), with high oral bioavailability (80–122%) of the released temsavir after administration of
the prodrug to preclinical species. However, dosing of the prodrug to humans revealed a short
plasma half-life of 1.5 h for temsavir, which was different from studies in animals. That necessitated
the development of an extended-release dosage form in order to achieve longer plasma exposure.
Subsequently, prodrug release in the ascending colon afforded an improved pharmacokinetic profile
of temsavir in humans. Therefore, this study showed for the first time that the expression of alkaline
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phosphatase in the lower GI tract is adequate to ensure effective phosphate prodrug conversion.
The phosphonooxymethyl prodrug of temsavir, fostemsavir, has completed phase 3 studies.
12. EphA2 Receptor Is a Key Player in the Metastatic Onset of Ewing Sarcoma
Highlighted by Catherine Guillou
Researchers of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a potential
new therapeutic target for Ewing sarcoma, the second most frequent bone cancer in children and
adolescents, and a tumor known for its aggressiveness and tendency to metastasize. They correlate the
EphA2 membrane receptor with the metastatic capacity of tumors in Ewing sarcoma. Researchers are
currently working on nanoengineering a molecule capable of blocking EphA2 and delivering drugs in
a targeted manner [12].
13. Discovery of Sulfonylfluoride Peptidomimetics as Targeted Covalent Inhibitors of
Prolyl Oligopeptidase
Highlighted by Michael Gütschow
Prolyl oligopeptidase (POP), a neuronal serine protease, cleaves post-proline bonds of small
peptides. POP has emerged as a promising target for the development of enzyme inhibitors, which have
already been shown to accelerate the clearance of aggregated α-synuclein, and are potentially useful
for the treatment of cognitive and neurodegenerative disorders.
Ernest Giralt’s group at the Barcelona Institute of Science and Technology, together with Rob M.J.
Liskamp’s group at the Utrecht Institute for Pharmaceutical Sciences, and further collaborators,
have performed a structure-based design to develop novel shape-complementary POP inhibitors by
assembling a peptidomimetic backbone of proline and 4-substituted proline as P1 and P2, tailored
hydrophobic moieties as P3 groups, and a new sulfonyl fluoride electrophilic warhead (synthesized
with difluoro(morpholino)sulfonium tetrafluoroborate) [13]. Several representatives of this chemotype
possessed single-digit nanomolar IC50 values and high membrane permeability (as determined in
PAMPA and MDCK assays). For a hit compound (kinac/Ki = 2 × 106 M−1s−1), irreversible reaction
with the active-site serine, more than 1000-fold selectivity for POP over two closely related proteases
(DPPIV and FAP) and low-nanomolar activity in human cells was demonstrated. Thus, novel and
highly potent POP inhibitors were introduced, whose selectivity ensures low cross-reactivity and
whose membrane permeability grants access to the CNS.
14. Nanobiotics: A Bioinspired Approach to Fight Antibacterial Resistance
Highlighted by Stefania Galdiero
Lei et al. [14] have envisioned a strategy to induce the self-assembling of an antimicrobial
peptide (AMP) in nanoparticle antibiotics (which they call nanobiotics) with excellent pharmacological
properties. The C-terminal myristoylated human α-defensin 5 (HD5) assembled nanobiotic shows
improved broad spectrum bactericidal activity in vitro and excellent tolerability in vivo. Furthermore,
they found that the nano-compound was able to protect mice against skin infections by MRSA
(methicillin resistant Staphylococcus aureus) and rescue them from Escherichia coli induced sepsis.
This strategy provides an opportunity for further developments in next generation antibiotics to
combat resistance which may be applied to the many natural AMPs. The authors present an innovative
and fascinating approach to design nano-structures for extensive biomedical applications against a
broad range of bacterial infections. A pioneering paper suggesting that the fight against antibacterial
resistance is still open!
15. Enrichment-triggered Prodrug Activation: A New Concept for Targeted-releasing
Prodrug Design
Highlighted by Hong Liu
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Controlled activation of prodrugs precisely in target sites is strongly needed in targeted therapy.
Creatively, by taking advantage of click reaction kinetics, Wang et al. [15] established a
concentration-sensitive platform approach for bioorthogonal prodrug activation. The authors designed
two different “click and release” systems to demonstrate the principle of the approach, using targeting
tethers for prodrug enrichment and bioorthogonal click chemistry for prodrug activation. In both cases,
the active drugs were released inside the mitochondrial matrix as a result of the enrichment-triggered
click reactions. Moreover, mitochondria-targeted delivery provided remarkable augmentation of
functional biological and therapeutic effects both in vitro and in vivo, compared with controls that did
not result in enrichment. Therefore, this method provided a platform for targeted prodrug design
that is amenable to conjugation with various molecules, and is not limited to cell-surface delivery.
Collectively, this work demonstrated a new concept of enrichment-triggered prodrug activation and
its critical feasibility of treating clinically relevant diseases, which may thus pave a new path for the
development of targeted-releasing prodrugs for clinical use.
16. Following the Assembly of the Hepatitis B Virus Capsid in Real Time by Mass-Spectrometry
Highlighted by Luigi A. Agrofoglio
The hepatitis B virus capsid (HBV) is a promising therapeutic target, since its assembly is crucial
to the completion of the viral life cycle. Using a charge detection mass spectrometry, researchers from
Indiana University [16] have tracked in real time the assembly of the icosahedral capsid. This approach
was able to investigate early intermediates in HBV capsid assembly as well as intact capsids, and data
support pathways that are (or are not) susceptible to trapping. A facile pathway from dimer to the
overgrown capsid occurs on an energy landscape that must be efficiently downhill. Salt concentration
can modify the assembly reaction; under higher salt conditions, around half of the products of the initial
assembly reaction have masses close to the T = 4 capsid, and the other half are stalled intermediates
which emerge abruptly at around 90 dimers. When incubated at room temperature, the 90-dimer
intermediates accumulate dimers, shift to higher mass, and merge with the capsid peak. These data
have a potential to help in designing small molecules that block the capsid assembly.
17. Unlocking Promising Avenues to Identify 'Novel' Therapeutic Target Proteins and
Candidate Drugs
Highlighted by Jean-Marc Sabatier
Blood plasma proteins remain poorly studied although they play a central role in many key
biological processes. The work by Sun et al. [17] gives a unique and more complete overview
of the genetic architecture of the human plasma proteome in healthy blood donors, with the
identification of almost 2000 genetic associations with ca. 1500 proteins (about 10% were so far identified).
Interestingly, the authors were able to 'link' some specific genetic variations to particular regions
that were reported to be associated with human diseases. This study contributed to a better
understanding of the inter-dependency between specific genetic variations, human diseases, and levels
of individual plasma proteins, thereby unlocking promising avenues for identifying 'novel' therapeutic
target proteins, candidate drugs (even known drugs applied to other diseases), and further highlighting
the potential risks of their use in humans.
18. MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate
Highlighted by Christopher Hulme
Despite continued set-backs with regulatory approvals of BACE inhibitors, first-in-class molecules
designed to mitigate AD continue to move along the value chain. MK-7622 and its progression
into Phase 2 trials is a timely success in lieu of the recent Merck BACE inhibitor failure in Phase 3.
Beshore et al. [18] describe lead optimization efforts to address physicochemical property and
safety issues, resulting in the discovery of the clinical candidate MK-7622, a very selective positive
Molecules 2018, 23, 1596 8 of 10
allosteric modulator of the M1 receptor. Interestingly, the pharmaceutical industry has pursued
the discovery of selectively activating M1 modulators for decades, and the publication of this
work with an associated structure should spur further efforts in the field to improve cognition in
Alzheimer’s patients.
19. A Novel Class of Docosahexaenoyl Ethanolamide (DHEA) Epoxides that Exhibit
Anti-Inflammatory and Anti-Tumorigenic Properties
Highlighted by George Kokotos
Dietary omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
have been shown to suppress tumor growth and progression by their conversion to anti-inflammatory
and anti-tumorigenic lipids. DHA and EPA can be converted by the N-acyl ethanolamine
synthesis pathway to endocannabinoids docosahexaenoyl ethanolamide (DHEA) and eicosapentaenoyl
ethanolamide (EPEA). Recently, the endogenous production of a previously unknown class of
ω-3 PUFA-derived lipid metabolites that originates from the crosstalk between endocannabinoid
and cytochrome P450 epoxygenase metabolic pathways was reported [19]. In neuroinflammation
studies, 17,18-epoxyeicosatetraenoic acid-ethanolamide (EEQ-EA) and 19,20-epoxydocosapentaenoic
acid-ethanolamide (EDP-EA) dose-dependently abated proinflammatory IL-6 cytokines while
increasing anti-inflammatory IL-10 cytokines, in part through cannabinoid receptor-2 activation.
More recently, EDP-EAs have been shown to exhibit anti-angiogenic, anti-tumorigenic, and anti-migratory
properties in osteosarcoma [20]. EDP-EAs were found to be increased by ~80% in metastatic lungs
versus normal mouse lungs, while significant differences in the apoptotic and anti-migratory potency
of the different EDP-EA regioisomers were observed. These naturally occurring molecules may be of
therapeutic significance to prevent metastasis of tumors.
20. Click Chemistry-based Discovery of Orally Active Hypoxia Inducing Factor Prolyl
Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia
Highlighted by Qidong You
Anemia is a frequent complication of chronic kidney disease (CKD), because failing kidneys
produce insufficient erythropoietin (EPO) to maintain normal red blood cell levels. Currently,
intravenous administration of recombinant human EPO (rhEPO) is the standard treatment to
ameliorate anemia. However, its serious side effects and the requirement for hospitalization
deter many patients. Today, inhibiting hypoxia-inducing factor prolyl hydroxylase 2 (HIF-PHD2)
by an orally active small molecule is regarded as an effective strategy to stabilize HIF-α and
then improve endogenous EPO level for anemia treatment. Recently, Wu et al. [21] reported
the details of a study to screen, optimize, and identify triazole compounds as potent HIF-PHD2
inhibitors based on click chemistry. Of particular note was the orally active HIF-PHD2 inhibitor
N-(5-(1-(3-(4-chlorophenyl)propyl)-1H-1,2,3-triazol-4-yl)-3-hydroxypicolinoyl)glycine (IC50 = 62 nM),
which was almost ten times more active than the phase III drug FG-4592 (IC50 = 591 nM). Furthermore,
it can upregulate the hemoglobin of anemic mice (120 g/L) to normal levels (160 g/L), with no apparent
toxicity observed in vivo. These results confirm that it is a promising candidate for the treatment of
renal anemia.
21. Acyclovir as an Ionic Liquid Cation or Anion Can Improve Aqueous Solubility
Highlighted by Paula A. C. Gomes
Ionic Liquids (ILs) have unique properties which are appealing for diverse applications,
from eco-friendly solvents (1st generation ILs) to tunable materials (2nd generation ILs). A decade
ago, the 3rd generation of ILs emerged based on use of active pharmaceutical ingredients (APIs)
to produce bioactive ILs (API-ILs) that may transform medicinal chemistry and the pharmaceutical
industry [22]. Exciting findings have been reported, including antimicrobial API-ILs which are
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active even against antibiotic-resistant bacteria [23]. Amongst the many benefits of API-ILs as drugs,
their water-solubility and tunability are the greatest, and have been addressed in a recent original
article by Shamshina et al. [24]. In this work, the solubility of the anti-retroviral drug acyclovir
in different media was tuned by the proper choice of the drug’s ionization state (cation or anion)
and counter-ion. This emblematic example highlights the urgent need to regulate pharmaceutical
development of API-ILs. After all, a paradigm shift has to happen before running out of options to
tackle the rise of one of the major health threats of our times, antibiotic resistance.
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